2022
Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer
Unlu S, Kim JW. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. Current Oncology Reports 2022, 24: 1619-1631. PMID: 35931885, DOI: 10.1007/s11912-022-01305-0.Peer-Reviewed Original ResearchConceptsPARP inhibitorsBRCA2 mutationsProstate cancerFDA approvalMetastatic prostate cancer patientsAccelerated FDA approvalDeleterious BRCA2 mutationsHRR gene mutationsObjective response ratePhase II studyMetastatic prostate cancerProstate cancer patientsPoly (ADP-ribose) polymerase (PARP) inhibitorsUS FDA approvalSomatic mutationsMCRPC patientsCombination regimenII studyClinical benefitRadium-223Cancer patientsStandard treatmentAndrogen receptorDNA damage repair pathwaysClinical development
2017
Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer
Kim JW, Shin MS, Kang Y, Kang I, Petrylak DP. Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer. Clinical Genitourinary Cancer 2017, 16: e469-e476. PMID: 29137877, PMCID: PMC5878980, DOI: 10.1016/j.clgc.2017.10.010.Peer-Reviewed Original ResearchConceptsCell death protein 1Death protein 1Metastatic prostate cancerT cellsProstate cancerPeripheral blood mononuclear cellsFrequency of CD27Frequency of CD8Immune checkpoint moleculesT cell subsetsBlood mononuclear cellsProtein 1Peripheral blood samplesImmune deficiency conditionsSignificant changesMean frequencyEM CD8Checkpoint moleculesFirst doseMemory CD8Osteoblastic metastasesRadium-223Cell subsetsCytokine productionMononuclear cells